Literature DB >> 8159599

Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus.

D Stanley1, B J McGrath, K C Lamp, M J Rybak.   

Abstract

STUDY
OBJECTIVE: To investigate the effects of pooled human serum (PHS) on the killing activity of vancomycin and teicoplanin against two isolates of Staphylococcus aureus from patients treated for endocarditis.
DESIGN: An in vitro assessment of antibiotic susceptibility and killing rates.
SETTING: An urban university teaching hospital. PATIENTS: Pooled human serum from patients treated for endocarditis.
INTERVENTIONS: Two clinical isolates of Staphylococcus aureus were obtained from patients treated for endocarditis. Media consisted of cation-supplemented Mueller-Hinton broth alone and in 1:1 dilutions with PHS, 2-hour heat-inactivated PHS (HI-PHS), ultrafiltrate (UF), and 2-hour heat-inactivated ultrafiltrate (HI-UF). Heat inactivation of PHS and UF was accomplished by treatment at 56 degrees C for 2 hours.
MEASUREMENTS AND MAIN RESULTS: Killing curves with vancomycin and teicoplanin were performed using drug concentrations of 45 micrograms/ml and a starting inoculum of approximately 1 x 10(6) colony-forming units (cfu)/ml. Bactericidal rates (-log cfu/ml/hr) were calculated from the slope of the killing curves over 0-12 hours (mean 3-8 replicates).
CONCLUSIONS: The killing activity of vancomycin in PHS and HI-PHS against both isolates was significantly greater than all other media tested (p < 0.0001). Ultrafiltrate tended to reverse this enhancement effect. Addition of PHS or UF did not enhance teicoplanin's killing activity against either isolate. Further investigations in our laboratory will determine if the factor is antibiotic class or organism specific.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8159599     DOI: 10.1002/j.1875-9114.1994.tb02786.x

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.

Authors:  G G Zhanel; I D Kirkpatrick; D J Hoban; A M Kabani; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

2.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 3.  Review on Usage of Vancomycin in Livestock and Humans: Maintaining Its Efficacy, Prevention of Resistance and Alternative Therapy.

Authors:  Panditharathnalage Nishantha Kumara Wijesekara; Wikum Widuranga Kumbukgolla; Jayaweera Arachchige Asela Sampath Jayaweera; Diwan Rawat
Journal:  Vet Sci       Date:  2017-01-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.